118 completed, 34 recruiting, 19 terminated, 18 not yet recruiting. 203 Phase 2, 41 Phase 1, 29 Phase 3.
Follow VA Office of Research and Development: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Device for Bladder Control for Men With SCI Noninvasive electrical stimulation device to improve bladder control - Neurogenic Bladder | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 12 | 2028-06-01 | 2026-06-25 |
| Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 / Phase 3 | Not yet recruiting | VA Office of Research and Development | 300 | 2027-10-01 | 2026-08-04 |
| Health Coaching and Veteran Reintegration Health Coaching, Enhanced treatment as usual - Reintegration Into Civilian Life | Phase 2 | Not yet recruiting | VA Office of Research and Development | 398 | 2027-07-01 | 2026-07-24 |
| Written Exposure Therapy Plus Adjunctive Methylphenidate Treatment for Veterans With PTSD Written Exposure Therapy (WET), methylphenidate (MPH), placebo (PBO) - PTSD - Post Traumatic Stress Disorder | Phase 2 | Not yet recruiting | VA Office of Research and Development | 138 | 2027-07-01 | 2026-10-29 |
| Remotely Administered tDCS to Improve Cognitive Function in Veterans With mTBI and PTSD Principal Investigator Transcranial direct current stimulation (tDCS), Cognitive training - Cognition, Brain Injuries | Phase 2 | Not yet recruiting | VA Office of Research and Development | 46 | 2027-05-24 | 2026-02-17 |
| Duloxetine and aeRobic Exercise to Improve Function in VEterans With Knee Osteoarthritis (DRIVE) Exercise, Duloxetine, Placebo - Knee Osteoarthritis, Pain | Phase 2 | Not yet recruiting | VA Office of Research and Development | 102 | 2027-03-01 | 2026-06-16 |
| Reducing Firearm Suicide Among Veterans: Evaluating the Effectiveness of Peer-Delivered Lethal Means Counseling Peer Engagement and Exploration of Responsibility and Safety, Active Control - Suicide, Secure Firearm Storage | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 100 | 2027-02-01 | 2026-10-26 |
| Psilocybin for Depression in Veterans Psilocybin, modafinil, zolpidem - Major Depression | Phase 2 | Not yet recruiting | VA Office of Research and Development | 150 | 2027-01-01 | 2026-10-26 |
| Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer capivasertib - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 32 | 2027-01-01 | 2026-10-05 |
| A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization Resistant Potato Starch, Maltodextrin - Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA) | Phase 2 | Not yet recruiting | VA Office of Research and Development | 120 | 2027-01-01 | 2026-08-28 |
| Allopregnanolone in Chronic Complex Traumatic Brain Injury Placebo, Allopregnanolone - Traumatic Brain Injury (TBI) | Phase 2 | Not yet recruiting | VA Office of Research and Development | 132 | 2026-12-01 | 2026-10-19 |
| Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial Pregnenolone, DHEA, Placebo - Chronic Low Back Pain | Phase 2 | Not yet recruiting | VA Office of Research and Development | 108 | 2026-12-01 | 2026-09-08 |
| Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab - Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm | Phase 2 | Not yet recruiting | VA Office of Research and Development | 30 | 2026-12-01 | 2026-10-06 |
| Retreat-Based Program for Violence-Exposed Women Veterans GRIT, GRI - Suicide Prevention | Phase 2 | Not yet recruiting | VA Office of Research and Development | 48 | 2026-12-01 | 2026-07-31 |
| Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy - Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 43 | 2026-11-01 | 2026-10-30 |
| Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE) Microbiota transplant therapy (MTT) capsules, Placebo capsule - Hepatic Encephalopathy, Cirrhosis | Phase 2 | Not yet recruiting | VA Office of Research and Development | 162 | 2026-10-30 | 2026-04-14 |
| Vascular Effects of SGLT2i in Non-diabetic CKD Empagliflozin, Placebo - Non-diabetic Chronic Kidney Disease | Phase 2 | Not yet recruiting | VA Office of Research and Development | 52 | 2026-10-01 | 2026-08-20 |
| LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial phase 2A Chlorthalidone, phase 2A Spironolactone, phase 2A Chlorthalidone + Spironolactone - Hypertension Treated With Antihypertensive Drugs, Chronic Kidney Disease, 3B and 4 | Phase 2 | Not yet recruiting | VA Office of Research and Development | 160 | 2026-10-01 | 2026-06-12 |
| Focused Ultrasound for PTSD in Veterans Brainsonix Ultrasound Device - Posttraumatic Stress Disorder | Phase 2 | Recruiting | VA Office of Research and Development | 60 | 2026-09-09 | 2026-09-15 |
| MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder Full Dose MDMA, MDMA-Assisted psychotherapy, Active Placebo Dose MDMA - Post Traumatic Stress Disorder, Alcohol Use Disorder | Phase 2 / Phase 3 | Recruiting | VA Office of Research and Development | 80 | 2026-05-18 | 2026-06-02 |
Showing 20 of 203. Sign in to see all of them.
Stress Disorders, Post-Traumatic (30) · Spinal Cord Injuries (13) · Motor Activity (10) · Alcoholism (9) · Depression (9) · Prostatic Neoplasms (8) · Sleep Apnea Syndromes (8) · Stroke (8) · Multiple Sclerosis (7) · Schizophrenia (7) · Renal Insufficiency, Chronic (6) · Tobacco Use Disorder (6) · Carcinoma, Non-Small-Cell Lung (5) · Cardiovascular Diseases (5) · Diabetes Mellitus (5)
Ketamine (6) · Pregnenolone (5) · Oxytocin (4) · Sodium Chloride (4) · Sugars (4) · Testosterone (4) · pembrolizumab (4) · Cholecalciferol (3) · Cognitive Behavioral Therapy (3) · Finasteride (3) · Midazolam (3) · Naltrexone (3) · 3-(2,4-dimethoxybenzylidene)anabaseine (2) · Abiraterone Acetate (2) · Acetylcysteine (2)
United States (203) · Canada (1)
Christine E. Marx, MD MA (4) · Ashraf Gorgey, PhD PT (3) · Carl J Stepnowsky, PhD (3) · Jennifer C Naylor, PhD (3) · Nasia Safdar, MD PhD (3) · Adriana M Hung, MD MPH (2) · Amy A Herrold, PhD BA (2) · Chong-Xian Pan, MD PhD (2) · Christine Marx, MD MA (2) · Gihyun Yoon, MD (2) · Jasmohan S. Bajaj, MD MS (2) · Joshua F Yarrow, PhD MS BS (2) · Matthew B. Rettig, MD (2) · Nicholas George Nickols, MD PhD (2) · Nithya Ramnath, MD (2)
PMID 11483142, PMID 12823166, PMID 15126771, PMID 15870612, PMID 16095473, PMID 16131943, PMID 16571581, PMID 16680620, PMID 16737798, PMID 17441783, PMID 17513285, PMID 17690799, PMID 18295436, PMID 18381905, PMID 18461049, PMID 19122865, PMID 20012639, PMID 20012982, PMID 20598832, PMID 20619405, PMID 20728875, PMID 20739168, PMID 20853931, PMID 21252493, PMID 21517712, PMID 21679267, PMID 21717386, PMID 21791356, PMID 21815915, PMID 21840138, PMID 21846661, PMID 21885958, PMID 22300564, PMID 22334806, PMID 22406052, PMID 22578037, PMID 22763197, PMID 22836351, PMID 22968110, PMID 23327503, PMID 23333585, PMID 23343764, PMID 23370525, PMID 23696427, PMID 23804455, PMID 24012740, PMID 24090622, PMID 24223036, PMID 24326421, PMID 24458967
R21AT004490 (2), 1IK2CX000547 (1), 1IK2CX000946-01 (1), 1IK2CX001397-01A2 (1), 1IK2CX001495-01 (1), 1IK2CX002225-01A1 (1), 1IK2CX002877-01A1 (1), 1IK2RD000464-01A2 (1), 1IK2RX001136-01A2 (1), 1IK2RX001180-01A2 (1), I01CX000264 (1), I01CX000569 (1), I01CX000982 (1), I01CX001414 (1), I01CX001761 (1)